Results 281 to 290 of about 68,914 (294)
Some of the next articles are maybe not open access.
Sirolimus: a comprehensive review
Expert Opinion on Pharmacotherapy, 2001Sirolimus (Rapamune), Wyeth-Ayerst, Madison, NJ) is a new, potent, immunosuppressant that is emerging as a foundation for long-term immunosuppressive therapy in renal transplantation. The drug acts during both co-stimulatory activation and cytokine-driven pathways via a unique mechanism: inhibition of a multifunctional serine-threonine kinase ...
openaire +2 more sources
Distribution of sirolimus in rat tissue
Clinical Biochemistry, 1997To examine the distribution of sirolimus (SRL, rapamycin), an immunosuppressive macrolide antibiotic, in the tissues of adult male Wistar-Furth rats following continuous intravenous infusion (CIVI) and repeated daily peroral gavage (PO).Animals received 14-day courses of SRL by either CIVI (0.04-0.4 mg/kg/day) or PO (0.4-1.6 mg/kg/day) administration ...
Stanislaw M. Stepkowski +3 more
openaire +3 more sources
Sirolimus after kidney transplantation [PDF]
BMJ, 2014 An uncertain future for sirolimus and other mTOR inhibitors The risk of cancer is increased after kidney transplantation and is predominantly attributed to oncogenic immunosuppression.1 It is a leading cause of death for kidney allograft recipients, and analyses of transplant registry data suggest that mortality related to cancer is on the increase.2 ...
openaire +2 more sources
Sirolimus therapy in cardiac transplantation
Transplantation Proceedings, 2003Rapamycin powerfully inhibits the progression of antigen-activated T cells through the cell cycle. In animal heart transplantation models, rapamycin therapy has been associated with profound immunosuppressive effects on host humoral and cellular responses.
Bojan Vrtovec, B. Radovancevic
openaire +3 more sources
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
New England Journal of Medicine, 2011To the Editor: McCormack and colleagues (April 28 issue) 1 state that the decline in lung function in patients with lymphangioleiomyomatosis (LAM) resumed in the sirolimus group after treatment ended and paralleled the reduction in the placebo group. Figure 2A of the article shows the speed of forced expiratory volume in 1 second (FEV 1 ) in the two ...
openaire +4 more sources
Sirolimus in advanced hemangioendothelioma.
Journal of Clinical Oncology, 201310565 Background: Haemangioendothelioma (HE) is a very rare vascular tumor. The epithelioid variant is characterized by a specific t(1;3)(p36.3;q25) translocation, resulting in the WWTR1-CAMTA1 fusion product. We retrospectively reviewed patients with HE treated with sirolimus, an mTOR inhibitor, at our institution. Methods: We identified 12 patients
Silvana Pilotti +12 more
openaire +2 more sources
Sirolimus in pediatric transplant recipients
Transplantation Proceedings, 2003The side effects of calcineurin inhibitors (CI) have a unique spectrum in pediatric recipients of organ transplants. These include a lifelong risk of mortality due to sepsis, a nearly 5% risk of renal failure from protracted exposure to CI, and a significantly higher risk of posttransplant lymphoproliferative disorder (PTLD) when compared with adults ...
openaire +3 more sources
Population pharmacokinetics of sirolimus
Clinical Pharmacology & Therapeutics, 1998Elena V. Mishina +3 more
openaire +3 more sources
Sirolimus for Lymphangioleiomyomatosis Lesions
New England Journal of Medicine, 2008Jim J. Egan +2 more
openaire +2 more sources